<ul> <li>2H18: Request pre-IND meeting with FDA gain agreement on development program</li> </ul>	to
<ul> <li>2H18: File IND for first-in-human study w LADR<sup>™</sup> drug conjugate</li> </ul>	ith
<ul> <li>By Sept 30, 2018: Signed term sheet for L major strategic alliance</li> </ul>	ADR™
<ul> <li>By Nov 30, 2018: LADR™ strategic alliance completion date and close</li> </ul>	ŧ
<ul> <li>By Sept 30, 2018: Signed term sheet for I major strategic alliance</li> </ul>	.ADR™
<ul> <li>By Nov 30, 2018: LADR<sup>™</sup> strategic alliane completion date and close</li> </ul>	e
<ul> <li>Strategic alliance partnership will determ next steps with pre-IND meeting, studies filing of IND for first-in-human study with LADR<sup>™</sup> drug conjugate</li> </ul>	and